Membrane organic anion-transporting polypeptides (OATPs) are responsible for the drug transmembrane transport within the human body. The function of OATP2B1 transporter can be inhibited by various natural compounds. Despite increased research interest in soya as a part of human diet, the effect of its active components to interact with hOATP2B1 has not been elucidated in a complex extent. This in vitro study examined the inhibitory effect of main soy isoflavones (daidzin, daidzein, genistin, genistein, glycitin, glycitein, biochanin A, formononetin) and their metabolites formed in vivo (S-equol, O-desmethylangolensin) towards human OATP2B1 transporter. MDCKII cells overexpressing hOATP2B1 were employed to determine quantitative inhibitory parameters of the tested compounds and to analyze mechanism/s of the inhibitory interaction. The study showed that aglycones of soy isoflavones and the main biologically active metabolite S-equol were able to significantly inhibit hOATP2B1-mediated transport. The Ki values for most of aglycones range from 1 to 20 μM. In contrast, glucosides did not exhibit significant inhibitory effect. The kinetic analysis did not indicate a uniform type of inhibition towards the hOATP2B1 although predominant mechanism of inhibition seemed to be competitive. These findings may suggest that tested soy isoflavones and their metabolites might affect transport of xenobiotics including drugs across tissue barriers via hOATP2B1.

Department of Organic and Bioorganic Chemistry Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1073. doi: 10.1007/s00210-018-1541-1. PubMed

Zobrazit více v PubMed

Biochem Pharmacol. 2010 Dec 1;80(11):1746-53 PubMed

Br J Nutr. 2006 Jan;95(1):204-13 PubMed

Mol Nutr Food Res. 2007 Jul;51(7):765-81 PubMed

Drug Metab Dispos. 2007 Apr;35(4):590-4 PubMed

J Pharm Sci. 2013 Sep;102(9):3418-26 PubMed

Maturitas. 2014 Aug;78(4):263-76 PubMed

Biomed Rep. 2013 Sep;1(5):697-701 PubMed

J Pharm Sci. 2017 Sep;106(9):2657-2663 PubMed

J Nutr. 2009 Nov;139(11):2037-43 PubMed

J Pharm Pharmacol. 2010 Jul;62(7):908-14 PubMed

Curr Drug Metab. 2015;16(2):124-40 PubMed

Arch Toxicol. 2015 Dec;89(12):2253-63 PubMed

Mol Aspects Med. 2013 Apr-Jun;34(2-3):396-412 PubMed

Drug Metab Dispos. 2018 May;46(5):692-696 PubMed

Drug Metab Dispos. 2006 Apr;34(4):577-82 PubMed

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):409-424 PubMed

J AOAC Int. 2006 Jul-Aug;89(4):1138-46 PubMed

Gastroenterology. 2001 Feb;120(2):525-33 PubMed

Arch Biochem Biophys. 2014 Oct 1;559:24-8 PubMed

Eur J Pharm Sci. 2012 May 12;46(1-2):79-85 PubMed

Mol Pharm. 2014 Oct 6;11(10):3547-55 PubMed

Drug Metab Pharmacokinet. 2010;25(6):521-30 PubMed

J AOAC Int. 2000 May-Jun;83(3):635-50 PubMed

Br J Pharmacol. 2012 Mar;165(5):1260-87 PubMed

Eur J Pharmacol. 2012 Feb 15;676(1-3):89-94 PubMed

Crit Rev Food Sci Nutr. 2008 Jun;48(6):538-52 PubMed

Adv Drug Deliv Rev. 2017 Jul 1;116:45-62 PubMed

Drug Metab Dispos. 2015 Apr;43(4):424-32 PubMed

Xenobiotica. 2018 Jan;48(1):73-78 PubMed

J Pharmacol Exp Ther. 2003 Aug;306(2):703-8 PubMed

Biopharm Drug Dispos. 2013 Jan;34(1):45-78 PubMed

J Womens Health (Larchmt). 2012 Jun;21(6):674-82 PubMed

Food Chem. 2017 May 1;222:67-73 PubMed

Adv Drug Deliv Rev. 2013 Oct;65(10):1340-56 PubMed

Expert Rev Clin Pharmacol. 2011 Nov;4(6):729-42 PubMed

Crit Rev Food Sci Nutr. 2016 Jul 29;56 Suppl 1:S95-S109 PubMed

Crit Rev Toxicol. 2014 Sep;44(8):696-724 PubMed

Xenobiotica. 2018 Jul;48(7):745-755 PubMed

J Steroid Biochem Mol Biol. 2003 Dec;87(4-5):285-99 PubMed

Drug Metab Dispos. 2005 Nov;33(11):1666-72 PubMed

Curr Drug Metab. 2014;15(8):791-807 PubMed

J Steroid Biochem Mol Biol. 1995 Aug;54(3-4):167-84 PubMed

Am J Clin Nutr. 1998 Dec;68(6 Suppl):1474S-1479S PubMed

Drug Metab Dispos. 2013 May;41(5):958-65 PubMed

Am J Clin Nutr. 2007 Apr;85(4):1050-6 PubMed